Dr. Qing Lin

Research Associate Professor

MSc Supervisor

Department: Dept. Pharmaceutics, West China School of Pharmacy, Sichuan University

Corresponding address: Lab 605-3, West China School of Pharmacy, West China Campus, Sichuan University, No. 17 People’s South Road, Chengdu, 610041, P.R China

E-mail: qinglin@scu.edu.cn 

Experience of Education & Research Work

2009.09–2013.06  BSc in Pharmacy, West China School of Pharmacy, Sichuan University

2013.09–2017.06  Ph.D in Pharmaceutics, West China School of Pharmacy, Sichuan University, 3+2+3 successive undergraduate and doctoral program (Hierophant: Prof. Zhirong Zhang)

2017.09–2020.09  Postdoctoral fellow/Research Associate in Dept. Pharmaceutics, West China School of Pharmacy, Sichuan University (Advisor: Prof. Zhirong Zhang)

2019.01–2020.01  Visiting Scientist in Dept. Chem Eng & Biotech, University of Cambridge, UK (Advisor: Prof. Nigel K.H. Slater FREng)

2020.09–till now  Research Associate Professor in in Dept. Pharmaceutics, West China School of Pharmacy, Sichuan University

2021.07–till now   MSc supervisor

Research Interest

Drug Delivery & Release Platforms

Fundings

1. The General Program of National Natural Science Foundation of China, No. 82273877, 2023.01-2026.12, Recipient

2. National Natural Science Foundation of China for Youth Scholars, No. 81803447, 2019.01-2021.12, Recipient

3. Natural Science Foundation of Sichuan Province for Youth Scholars, No. 23NSFSC3777, 2023.01-2024.12, Recipient

4. China Postdoctoral Science Foundation, No. 2018M633388, 2019.01-2022.12, Recipient

5. Postdoctoral Interdisciplinary Innovation Program of Sichuan University, 2019. 01-2020.09, Recipient

6. Fundamental Research Funds for the Central Universities of China, No. 2018SCU12025, 2018. 01-2019.12, Recipient

Selected Publications

[1] Yu Fu, Wei Liu, Luyao Wang, Biyue Zhu, Mengke Qu, Liuqing Yang, Xun Sun, Tao Gong, Zhi-rong Zhang, Qing Lin*, Ling Zhang*. Erythrocyte-membrane-camouflaged nanoplatform for intravenous glucose-responsive insulin delivery. Advanced Functional Materials, 2018, 28 (41): 1802250.

[2] Kejun Jiang^#, Xu Song^#, Liuqing Yang, Lin Li, Zhuoya Wan, Xun Sun, Tao Gong, Qing Lin*, Zhirong Zhang*. Enhanced antitumor and anti-metastasis efficacy against aggressive breast cancer with a fibronectin-targeting liposomal doxorubicin. Journal of Controlled Release, 2018, 271: 21-30.

[3] Luyao Wang, Mengke Qu, Shiqi Huang, Yu Fu, Liuqing Yang, Shanshan He, Lin Li, Zhirong Zhang, Qing Lin*, Ling Zhang*. A novel α-enolase-targeted drug delivery system for high efficacy prostate cancer therapy. Nanoscale, 2018, 10: 13673-13683.

[4] Xun Hu,  Mengdi Jia,  Yu Fu,  Pei Zhang,  Zhirong Zhang,  Qing Lin*. A novel low-toxic derivative of celastrol maintains protective effect against acute renal injury. ACS Omega, 2018, 3 (3): 2652-2660.

[5] Bingjie Zhou, Min Li, Xiaomin Xu, Lan Yang, Meiling Ye, Yan Chen, Jiayi Peng, Linyu Xiao, Luyao Wang, Shiqi Huang, Ling Zhang, Qing Lin*, Zhirong Zhang. Integrin α₂β₁ targeting DGEA-modified liposomal doxorubicin enhances anti-tumor efficacy against breast cancer. Molecular Pharmaceutics, 2021, 18 (7): 2634-2646.

[6] Yu Fu, Leilei Wang, Wei Liu, Lan Yang, Lin Li, Luyao Wang, Xun Sun, Zhirong Zhang, Qing Lin*, Ling Zhang*. OX40L blockade cellular nanovesicles for autoimmune diseases therapy. Journal of Controlled Release, 2021, 337: 557-570.

[7] Qiang Zhang, Yikun Han, Honglin Xiang, Min Li, Lan Yang, Qiang Liu, Yan Zhang, Zhirong Zhang, Qing Lin*, Ling Zhang*. Biopharmaceutical, preclinical pharmacokinetic and pharmaco-dynamic investigations of an orally administered novel 3-nbutylphthalide prodrug for ischemic stroke treatment. European Journal of Pharmaceutical Sciences, 2022, 180: 106308.

[8] Qing Lin, Mengke Qu, Hirak K. Patra, Shanshan He, Luyao Wang, Xun Hu, Linyu Xiao, Yu Fu, Tao Gong, Qin He, Ling Zhang*, Xun Sun, Zhirong Zhang. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer. Journal of Ethnopharmacology, 2020, 247: 112283.

[9] Qing Lin, Yan Li, Meng-Ke Qu, Xing Liu, Zhi-Rong Zhang, Ling Zhang. Preliminary Investigation on Difference of Protein Compositions Between DC2. 4 Cells and Their Derived Exosomes by nanoLC-MS/MS. Journal of Sichuan University Medical Science, 2020, 51(1): 81-86.

[10] Qing Lin, Mengke Qu, Bingjie Zhou, Hirak K. Patra, Zihan Sun, Qiong Luo, Wenyu Yang, Yongcui Wu, Yu Zhang, Lin Li, Lang Deng, Leilei Wang, Tao Gong, Qin He, Ling Zhang*, Xun Sun, Zhirong Zhang. Exosome-like nanoplatform modified with targeting ligand improves anti-cancer and anti-inflammation effects of imperialine. Journal of Controlled Release, 2019, 311: 104-116.